期刊
NEURO-ONCOLOGY
卷 16, 期 10, 页码 1304-1312出版社
OXFORD UNIV PRESS INC
DOI: 10.1093/neuonc/nou045
关键词
glioblastoma; glioma; immunotherapy; IL13R alpha 2; toxin
资金
- Roger Williams Medical Center Brain Tumor Research Fund
Glioblastoma multiforme (GBM) remains one of the most lethal primary brain tumors despite surgical and therapeutic advancements. Targeted therapies of neoplastic diseases, including GBM, have received a great deal of interest in recent years. A highly studied target of GBM is interleukin-13 receptor alpha chain variant 2 (IL13R alpha 2). Targeted thepies against IL13R alpha 2 in GBM include fusion chimera proteins of IL-13 and bacterial toxins, nanoparticles, and oncolytic viruses. In addition, immunotherapies have been developed using monoclonal antibodies and cell-based strategies such as IL13R alpha 2-pulsed dendritic cells and IL13R alpha 2-targeted chimeric antigen receptor-modified T cells. Advanced therapeutic development has led to the completion of phase I clinical trials for chimeric antigen receptor-modified T cells and phase III clinical trials for IL-13-conjugated bacterial toxin, with promising outcomes. Selective expression of IL13R alpha 2 on tumor cells, while absent in the surrounding normal brain tissue, has motivated continued study of IL13R alpha 2 as an important candidate for targeted glioma therapy. Here, we review the preclinical and clinical studies targeting IL13R alpha 2 in GBM and discuss new advances and promising applications.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据